发布求助
文献互助 智能选刊 最新文献

NUCLEAR MEDICINE REVIEW最新文献

筛选
英文 中文
Prostate-specific membrane antigen expression in intracranial lesions - a review of the primary, metastatic, and nonneoplastic lesions. 前列腺特异性膜抗原在颅内病变中的表达——原发、转移和非肿瘤性病变的综述。
IF 0.9
NUCLEAR MEDICINE REVIEW Pub Date : 2023-01-01 DOI: 10.5603/nmr.97019
Kacper Pełka, Aleksandra Bodys-Pełka, Jolanta Kunikowska
{"title":"Prostate-specific membrane antigen expression in intracranial lesions - a review of the primary, metastatic, and nonneoplastic lesions.","authors":"Kacper Pełka, Aleksandra Bodys-Pełka, Jolanta Kunikowska","doi":"10.5603/nmr.97019","DOIUrl":"10.5603/nmr.97019","url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA) is a membrane protein originally discovered in prostate cancer cells. It is widely used at all stages of prostate cancer diagnosis. Several studies have highlighted its possible wide application in other cancers. This review discusses the potential use of positron emission tomography with labelled PSMA for the diagnosis or differentiation of intracranial lesions. Given the numerous reports on the usefulness of PSMA in the diagnosis of brain tumours of glial origin, the focus is on lesions of a different aetiology.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138177544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurolymphomatosis diagnosed on [18F]FDG PET/CT. [18F]FDG PET/CT诊断神经淋巴瘤
IF 0.6
NUCLEAR MEDICINE REVIEW Pub Date : 2023-01-01 DOI: 10.5603/NMR.2023.0012
Yassir Benameur, Omar Ait Sahel, Salah Nabih Oueriagli, Abderrahim Doudouh
{"title":"Neurolymphomatosis diagnosed on [18F]FDG PET/CT.","authors":"Yassir Benameur, Omar Ait Sahel, Salah Nabih Oueriagli, Abderrahim Doudouh","doi":"10.5603/NMR.2023.0012","DOIUrl":"10.5603/NMR.2023.0012","url":null,"abstract":"<p><p>Fluorine-18-deoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) has been shown to be superior to other conventional imaging modalities in the detection of extra-nodal lymphomatous localizations. Especially in neurolymphomatosis which is rarely encountered in high-grade lymphomas. We report a case of a woman diagnosed with non-Hodgkin lymphoma, whose initial staging with [18F]FDG PET/CT showed increased [18F]FDG uptake along the brachial and sacral plexuses. [18F]FDG PET/CT remains the most appropriate diagnostic tool in these cases, whose prognosis is often poor.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43206973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of [18F]FDG PET/CT in the differential diagnosis of a supraclavicular lump: neurofibromatosis disease. [18F]FDG PET/CT在锁骨上肿块:神经纤维瘤病鉴别诊断中的作用
IF 0.6
NUCLEAR MEDICINE REVIEW Pub Date : 2023-01-01 DOI: 10.5603/NMR.a2022.0043
Ana Moreno-Ballesteros, María De Bonilla-Candau, Javier Mohigefer, Marta Moreno-Ballesteros, Francisco Javier Garcia-Gomez
{"title":"Role of [18F]FDG PET/CT in the differential diagnosis of a supraclavicular lump: neurofibromatosis disease.","authors":"Ana Moreno-Ballesteros, María De Bonilla-Candau, Javier Mohigefer, Marta Moreno-Ballesteros, Francisco Javier Garcia-Gomez","doi":"10.5603/NMR.a2022.0043","DOIUrl":"10.5603/NMR.a2022.0043","url":null,"abstract":"<p><p>We report a 31-year-old male with a history of left forearm neuroma surgically removed, consulting for a supraclavicular bultoma congruent with the supradiaphragmatic lymphoproliferative syndrome in computed tomography (CT) scan. [18F]FDG PET/CT images helped to establish the most diagnostic yield lesion for the biopsy, and allowed an accurate staging of the neurofibromatosis (NF) disease, leading to the most appropriate therapeutic option for the patient.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46103723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Confirmation of PSMA expression measured on [68Ga]Ga-PSMA PET/CT by immunohistochemistry in prostate adenocarcinoma. [68Ga]Ga-PSMA PET/CT免疫组化检测前列腺癌组织中PSMA表达的证实
IF 0.9
NUCLEAR MEDICINE REVIEW Pub Date : 2023-01-01 DOI: 10.5603/NMR.2023.0008
Tarik Sengoz, Nilay Sen Turk, Yusuf Ozlulerden, Sinan Celen, Aziz Gultekin, Olga Yaylali, Dogangun Yuksel
{"title":"Confirmation of PSMA expression measured on [68Ga]Ga-PSMA PET/CT by immunohistochemistry in prostate adenocarcinoma.","authors":"Tarik Sengoz,&nbsp;Nilay Sen Turk,&nbsp;Yusuf Ozlulerden,&nbsp;Sinan Celen,&nbsp;Aziz Gultekin,&nbsp;Olga Yaylali,&nbsp;Dogangun Yuksel","doi":"10.5603/NMR.2023.0008","DOIUrl":"https://doi.org/10.5603/NMR.2023.0008","url":null,"abstract":"<p><strong>Background: </strong>Our aim is to determine the accuracy of [68Ga]Ga-PSMA PET/CT in showing PSMA expression in primary prostate cancer and to investigate the relationship between SUVmax and immunohistochemical PSMA expression, Gleason score, and PSA value.</p><p><strong>Material and methods: </strong>We retrospectively analyzed 66 male patients who were diagnosed with primary prostate adenocarcinoma, underwent pre-treatment [68Ga]Ga-PSMA PET/CT examination for staging, and performed radical prostatectomy between March 2018-August 2020. Immunohistochemical staining was applied to the radical prostatectomy specimens of all patients to detect PSMA expression. The results were evaluated as an immunoreactive score (IRS) and a modified IRS was obtained. Gleason score groups and prostate-specific antigen (PSA) serum values of the patients were obtained from the patient files.</p><p><strong>Results: </strong>The high SUVmax of primary prostate tumors was significantly correlated with a high modified IRS score (score 2; 3), high PSA value, high Gleason score, and metastasis. In correlation analysis, a positive correlation was found between SUVmax and PSA value and modified IRS score (r = 0.69, p = 0.001; r = 0.39, p = 0.001). In addition, there was a statistically significant weak correlation between PSA serum concentration and modified IRS scores (r = 0.267; p = 0.03). In regression analysis, the percentage of positive cells had a statistically significant and increasing effect on SUVmax (p = 0.031; std beta = 0.268; 95% CI = 0.231-4.596).</p><p><strong>Conclusions: </strong>In prostate adenocarcinoma, SUVmax of the primary tumor in [68Ga]Ga-PSMA PET/CT correlates with immunohistochemical PSMA expression. In addition, high SUVmax is associated with markers of poor prognoses, such as high PSMA expression, PSA value, and Gleason score.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9697826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vertebral photopenia on [67Ga]Ga-citrate and [18F]FDG PET/CT imaging in a patient with non-Hodgkin lymphoma. [67Ga]枸橼酸镓和[18F]FDG PET/CT成像显示非霍奇金淋巴瘤患者椎体光减少。
IF 0.9
NUCLEAR MEDICINE REVIEW Pub Date : 2023-01-01 DOI: 10.5603/NMR.a2022.0042
Georgios Meristoudis, Ioannis Ilias, Vasilios Giannakopoulos
{"title":"Vertebral photopenia on [67Ga]Ga-citrate and [18F]FDG PET/CT imaging in a patient with non-Hodgkin lymphoma.","authors":"Georgios Meristoudis,&nbsp;Ioannis Ilias,&nbsp;Vasilios Giannakopoulos","doi":"10.5603/NMR.a2022.0042","DOIUrl":"https://doi.org/10.5603/NMR.a2022.0042","url":null,"abstract":"<p><p>A cold vertebral defect is an uncommon finding, especially in Gallium-67-citrate ([67Ga]Ga-citrate) - and [18F]fluorodeoxyglucose ([18F]FDG) - avid lymphomas, representing a diagnostic challenge. Here, we present the case of a patient with non-Hodgkin lymphoma (NHL), in whom the [67Ga]Ga-citrate and [18F]FDG scans showed a diffuse skeletal uptake pattern with concomitant appearance of a cold vertebral defect. Awareness of the different causes of such uptake patterns and accurate clinical information is important to avoid misinterpretation of nuclear studies in oncologic patients.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10801902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An approach to develop personalized radiopharmaceuticals by modifying 2-[18F]fluoro-2-deoxy-D-glucose (2-[18F]FDG). 通过修饰2-[18F]氟-2-脱氧-D-葡萄糖（2-[18F]FDG）开发个性化放射性药物的方法。
IF 0.9
NUCLEAR MEDICINE REVIEW Pub Date : 2023-01-01 DOI: 10.5603/nmr.93869
Gergana Simeonova, Boyan Todorov
{"title":"An approach to develop personalized radiopharmaceuticals by modifying 2-[18F]fluoro-2-deoxy-D-glucose (2-[18F]FDG).","authors":"Gergana Simeonova,&nbsp;Boyan Todorov","doi":"10.5603/nmr.93869","DOIUrl":"https://doi.org/10.5603/nmr.93869","url":null,"abstract":"<p><strong>Background: </strong>A challenge for modern medicine is the development of clinical protocols for precise diagnosis and therapy. This study aimed to propose a simple method for modification of 2-[18F]FDG used routinely in hospitals in a way, appropriate for patients' personalized radiopharmaceuticals approach.</p><p><strong>Material and methods: </strong>For the purposes of the presented study chemo selective method for indirect radiofluorination was applauded to custom synthesized aminooxy- and hydrazine-functionalized tetrazines for 18F-glycolation via oxime or hydrazone formation. 2-[18F]FDG produced with medical baby cyclotron in Nuclear Medicine Clinic at the University Hospital St. Marina-Varna, was used. Thin layer chromatography (TLC) and radio TLC were used to follow the progress of synthesis and to determine radio chemical yield (RCY).</p><p><strong>Results: </strong>The 2-[18F]FDG was modified with two bifunctional tetrazines aminooxy-acetic acid-6-(2-aminooxy-acetoxy)-[1,2,4,5] tetrazin-3-yl ester (Tz1) and {3-[4-(6-phenyl-[1,2,4,5]tetrazin-3-yl)-phenoxy]-propyl}-hydrazine (Tz2) via oxime and hydrazone formation. The radiolabeling was carried out as one-pot reaction with following parameters: temperature 70-75°C; catalyst p- diaminobenzene (Cat.); pH = 4.2; time 30 minutes; RCY = 70-99%. The radiolabeled tetrazines are appropriate for further bioorthogonal (pretargeting) strategy by click reactions with trans-cyclooctene conjugated bioactive molecules. The methodology is applicable to standard clinical conditions.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41165366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
123I-ioflupane SPECT in the assessment of Parkinson’s disease in a patient with retinitis pigmentosa 123I-ioflupane SPECT评估一例视网膜色素变性患者的帕金森病
IF 0.9
NUCLEAR MEDICINE REVIEW Pub Date : 2022-10-27 DOI: 10.5603/nmr.a2022.0040
Francesco Dondi, M. Gregorelli, D. Albano, F. Bertagna, R. Giubbini
{"title":"123I-ioflupane SPECT in the assessment of Parkinson’s disease in a patient with retinitis pigmentosa","authors":"Francesco Dondi, M. Gregorelli, D. Albano, F. Bertagna, R. Giubbini","doi":"10.5603/nmr.a2022.0040","DOIUrl":"https://doi.org/10.5603/nmr.a2022.0040","url":null,"abstract":"","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42306672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm. 神经性内分泌肿瘤患者肽受体放射性核素与镥-177和钇-90治疗的肝脏并发症。
IF 0.9
NUCLEAR MEDICINE REVIEW Pub Date : 2022-01-01 DOI: 10.5603/NMR.a2022.0016
Barbara Bober, Marek Saracyn, Arkadiusz Lubas, Maciej Kolodziej, Dorota Brodowska-Kania, Waldemar Kapusta, Grzegorz Kaminski
{"title":"Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm.","authors":"Barbara Bober,&nbsp;Marek Saracyn,&nbsp;Arkadiusz Lubas,&nbsp;Maciej Kolodziej,&nbsp;Dorota Brodowska-Kania,&nbsp;Waldemar Kapusta,&nbsp;Grzegorz Kaminski","doi":"10.5603/NMR.a2022.0016","DOIUrl":"https://doi.org/10.5603/NMR.a2022.0016","url":null,"abstract":"<p><p>Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors originating from neuroendocrine cells spread throughout the body, forming the so-called diffuse endocrine system. The gold standard in treating unresectable or disseminated, progressive, and well-differentiated NENs is therapy with radiolabeled somatostatin analogs (peptide receptor radionuclide therapy - PRRT). PRRT is a method based on peptides combined with beta-emitting radionuclides. The study aimed to assess the early and long-term liver complications after administration of Lutetium-177 or Lutetium-177 combined with Yttrium-90. We enrolled 27 patients treated with [177Lu]Lu-DOTATATE with an activity of 7.4 GBq (200 mCi) and 9 patients received the tandem treatment [90Y]Y-DOTATATE + [177Lu]Lu-DOTATATE with an activity of 3.7 GBq (50 mCi + 50 mCi). In the assessment of early as well as long-term complications, no significant effect of the applied treatment on the parameters of liver injury was found. Regarding liver function PRRT was a safe treatment for patients with highly or moderately differentiated, unresectable, or diffuse NENs.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39764934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The scintigraphic diagnosis of cardiac amyloidosis. An expert opinion endorsed by the Section of Nuclear Medicine of the Polish Cardiac Society and the Polish Nuclear Medicine Society. 心脏淀粉样变的影像学诊断。波兰心脏学会和波兰核医学学会核医学部认可的专家意见。
IF 0.9
NUCLEAR MEDICINE REVIEW Pub Date : 2022-01-01 DOI: 10.5603/NMR.a2022.0033
Katarzyna Holcman, Miroslaw Dziuk, Jacek Grzybowski, Anna Teresinska, Bogdan Malkowski, Diana Jedrzejuk, Bogna Brockhuis, Rafał Czepczynski, Lidia Tomkiewicz-Pajak, Magdalena Kostkiewicz
{"title":"The scintigraphic diagnosis of cardiac amyloidosis. An expert opinion endorsed by the Section of Nuclear Medicine of the Polish Cardiac Society and the Polish Nuclear Medicine Society.","authors":"Katarzyna Holcman,&nbsp;Miroslaw Dziuk,&nbsp;Jacek Grzybowski,&nbsp;Anna Teresinska,&nbsp;Bogdan Malkowski,&nbsp;Diana Jedrzejuk,&nbsp;Bogna Brockhuis,&nbsp;Rafał Czepczynski,&nbsp;Lidia Tomkiewicz-Pajak,&nbsp;Magdalena Kostkiewicz","doi":"10.5603/NMR.a2022.0033","DOIUrl":"https://doi.org/10.5603/NMR.a2022.0033","url":null,"abstract":"<p><p>Amyloid transthyretin cardiomyopathy is a progressive disease that confers significant mortality. While it is relatively rare, the frequency of diagnoses has risen with the increased contribution of novel diagnostic approach over the last decade. Traditionally tissue biopsy was considered to be a gold standard for amyloidosis diagnosis. However, there are significant limitations in the wide application of this approach. A noninvasive imaging-based diagnostic algorithm has been substantially developed in recent years. Establishing radionuclide imaging standards may translate into a further enhancement of disease detection and improving prognosis in the group of patients. Therefore we present in the following document current evidence on the scintigraphic diagnosis of cardiac transthyretin amyloidosis. Moreover, we present standardized protocol for the acquisition and interpretation criteria in the scintigraphic evaluation of cardiac amyloidosis.</p>","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Note. 编辑说明。
IF 0.6
NUCLEAR MEDICINE REVIEW Pub Date : 2022-01-01 DOI: 10.5603/NMR.2022.0001
Grzegorz Kamiński
{"title":"Editorial Note.","authors":"Grzegorz Kamiński","doi":"10.5603/NMR.2022.0001","DOIUrl":"10.5603/NMR.2022.0001","url":null,"abstract":"","PeriodicalId":44718,"journal":{"name":"NUCLEAR MEDICINE REVIEW","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39902627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信